Catalyst Pharm Inc (CPRX)
21.71 -0.82 (-3.64%)
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for individuals with rare neurological and neuromuscular diseases. The company’s primary emphasis is on conditions like myasthenia gravis, creating targeted treatments that aim to improve patient outcomes and quality of life. Catalyst Pharmaceuticals is committed to advancing its drug pipeline through research, development, and collaboration, striving to address unmet medical needs in the rare disease landscape. With a patient-centered approach, the company aims to transform the treatment paradigm in its specialized therapeutic areas.
Previous Close | 22.53 |
---|---|
Open | 22.52 |
Bid | 21.74 |
Ask | 22.00 |
Day's Range | 21.50 - 22.59 |
52 Week Range | 13.00 - 24.27 |
Volume | 903,581 |
Market Cap | 2.23B |
PE Ratio (TTM) | 18.40 |
EPS (TTM) | 1.2 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 1,152,235 |
News & Press Releases
Despite its impressive fundamentals, NASDAQ:CPRX remains undervalued.chartmill.com
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX), an undervalued stock with good fundamentals.
Via Chartmill · December 3, 2024
Why NASDAQ:CPRX qualifies as a high growth stock.chartmill.com
Should you consider CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) for high growth investing?
Via Chartmill · December 3, 2024
Is NASDAQ:CPRX on the Verge of a Major Breakout as a Strong Growth Stock?chartmill.com
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX)—A High-Growth Stock Gearing Up for Its Next Upward Move.
Via Chartmill · November 25, 2024
Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ List
By Catalyst Pharmaceuticals, Inc. · Via GlobeNewswire · November 25, 2024
NASDAQ:CPRX is showing good growth, while it is not too expensive.chartmill.com
Via Chartmill · November 20, 2024
NASDAQ:CPRX is an undervalued gem with solid fundamentals.chartmill.com
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) appears to be flying under the radar despite its strong fundamentals.
Via Chartmill · November 12, 2024
Why the growth investor may take a look at CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX).chartmill.com
Why the growth investor may take a look at CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX).
Via Chartmill · November 7, 2024
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
CORAL GABLES, Fla., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate in the upcoming investor conferences detailed below.
By Catalyst Pharmaceuticals, Inc. · Via GlobeNewswire · November 19, 2024
BioNTech Stock Got A IBD RS Rating Liftinvestors.com
Via Investor's Business Daily · November 14, 2024
Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work
CORAL GABLES, Fla., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it has been named on the BioSpace 2025 Best Places to Work. Catalyst is among 50 U.S. operating employers on the Best Places to Work list. The recipients are recognized as the most sought-after in the industry by the life sciences community.
By Catalyst Pharmaceuticals, Inc. · Via GlobeNewswire · November 13, 2024
Vericel Stock Sees RS Rating Shoot Higherinvestors.com
The Relative Strength (RS) Rating for Vericel stock entered a higher percentile Monday, as it got a lift from 69 to 79.
Via Investor's Business Daily · November 11, 2024
NASDAQ:CPRX, a growth stock which is not overvalued.chartmill.com
Via Chartmill · October 30, 2024
Smaller Cap Biotechs Are In Season: How Are We Doing?talkmarkets.com
SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range.
Via Talk Markets · November 7, 2024
Catalyst Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Provides Corporate Update
By Catalyst Pharmaceuticals, Inc. · Via GlobeNewswire · November 6, 2024
Why NASDAQ:CPRX Is a Promising High-Growth Stock in the Midst of Consolidation.chartmill.com
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX): a strong growth stock preparing for the next leg up?.
Via Chartmill · November 4, 2024
Biotech Momentum Trades For The Q4 Rallytalkmarkets.com
The biotech sector made an interim peak in late February followed by an active summer in very choppy trading.
Via Talk Markets · October 29, 2024
Catalyst Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 6, 2024
By Catalyst Pharmaceuticals, Inc. · Via GlobeNewswire · October 22, 2024
Amphastar Casts Wide Net, Hauls In Profits, Gets Rating Upgradeinvestors.com
Amphastar hit an all-time high in August 2023 and consolidated. It could be forming the right side of a cup base that started in January.
Via Investor's Business Daily · October 15, 2024
NASDAQ:CPRX—Positioned as a High-Growth Stock, Ready for a Potential Breakout.chartmill.com
Exploring the Growth Potential of CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) as It Nears a Breakout.
Via Chartmill · October 14, 2024
Alkermes Stock Jumps Nearly 30% In 3 Months Amid Hefty Profitsinvestors.com
Alkermes develops treatments for neurodegenerative diseases (conditions that damage and destroy parts of the nervous system) and cancer.
Via Investor's Business Daily · October 14, 2024
Looking for growth without the hefty price tag? Consider NASDAQ:CPRX.chartmill.com
While growth is established for CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX), the stock's valuation remains reasonable.
Via Chartmill · October 9, 2024
Catalyst Pharmaceuticals Donates $100,000 to the American Red Cross Hurricane Helene Relief Efforts
CORAL GABLES, Fla., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "the Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel therapies for patients with rare diseases, today announced that it has contributed $100,000 to the American Red Cross to support ongoing relief efforts for communities impacted by Hurricane Helene.
By Catalyst Pharmaceuticals, Inc. · Via GlobeNewswire · October 8, 2024
Catalyst Pharmaceuticals to Participate in the BofA Securities CNS Therapeutics Virtual Conference 2024
CORAL GABLES, Fla., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate in the upcoming BofA Securities CNS Therapeutics Virtual Conference 2024 on Monday, October 7, 2024.
By Catalyst Pharmaceuticals, Inc. · Via GlobeNewswire · October 1, 2024
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE® in Japan
CORAL GABLES, Fla., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that its sub-licensee in Japan, DyDo Pharma, Inc., ("DyDo") has reported that the Ministry of Health, Labor and Welfare of Japan has approved DyDo's New Drug Application ("NDA") to commercialize FIRDAPSE® (amifampridine) Tablets 10 mg for treatment of patients with Lambert-Eaton Myasthenic Syndrome ("LEMS") in Japan. This approval marks a pivotal advancement in the treatment of LEMS, a rare autoimmune disorder that can severely impact quality of life and represents a significant step forward in addressing the unmet needs of patients affected by LEMS in Japan.
By Catalyst Pharmaceuticals, Inc. · Via GlobeNewswire · September 24, 2024